Notice: Undefined index: HTTP_ACCEPT_LANGUAGE in /DATA/web/docroots/www.alscience.it/include/multilang.php on line 40
ALScience
WELCOME
About us
This site is dedicated to scientific community working on ALS. Our aim is to optimize researchers time and efforts by providing updated, well organized information on novel findings, available resources and research support.
AriSLA - The Foundation for research on ALS - has been set up to make ALS research investments more effective and efficient, to speed up the clinical research impact e and to provide patients with better care, improved conditions and life expectancy. Its aim is to boost Italian excellencies in basic, clinical and technological research. The Foundation founders are Fondazione Cariplo, Fondazione Telethon, Fondazione Vialli and Mauro and AISLA.

 

 

E-Rare-3 Call for Proposals 2016 (JTC 2016)

 Clinical research for new therapeutic uses of already existing molecules (repurposing) in rare diseases

The E-Rare Call for projects intends to"promote clinical and pre-clinical proof of concept studies for the potential application of medicinal products that are either already marketed or having achieved a significant stage in the development process in rare indications. Projects should aim at discovering new therapeutic uses for Agents whose clinical safety has already been documented to move quickly into proof of concept trials in the selected rare diseases' patient population".


The Call is open for two type of projects as follow

  • Type A: Preclinical studies to verify target engagement and to perform additional toxicity testing if necessary (for example in the case of paediatric indications where juvenile animal studies might be warranted)in a disease model for a maximum period of one year followed by the implementation of Phase 1b or Phase 2a clinical trials at the beginning of the second year of the project;
  • Type B: Milestone-driven Phase 2 clinical trials to demonstrate that the Agent modulates the target and has the potential to yield the desired clinical outcome in the proposed disease population for a period up to three years.

Further information can be found at

http://first.aster.it/_aster_/viewNews?ID=34639

 




     
     
     
Powered by Sofonisba